Inflammatory Bowel Diseases Clinical Trial
Official title:
Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit - an Interprofessional Approach
The advancement in life-saving technologies and clinical expertise in the care of extremely
premature infants, have resulted in the development of large neonatal intensive care units
(NICU). It has been suggested that reconstruction of megaunits of neonatal intensive care to
smaller care units with specific patient population and clinical team providers will be
essential to maintain optimal teamwork, quality of care and patient outcome.
Despite the growing knowledge around the need for reconstruction of large NICUs to smaller
units of care, there is no evidence regarding the safety and efficacy of microsystem model
of care on the key aspects of health care. At the McMaster Children's Hospital (MCH), we
planned a change from standard model of care to the microsystem model of care and therefore
we aimed to prospectively assess the effect of this organizational change on the variable
aspects of health care.
A working group met weekly to formulate the implementation planning, to review the
adaptation and adjustment process and to ascertain the quality of implementation following
the initiation of the microsystem model.
The study was retrospectively registered.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | December 2017 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion criteria: - All preterm and term infants admitted to McMaster Children's Hospital NICU Exclusion criteria: - no exclusion criteria |
Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Canada | Faculty of Health Science, McMaster Children's Hospital | Hamilton | Ontario |
Lead Sponsor | Collaborator |
---|---|
McMaster Children's Hospital |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of stress level of Health Care Professional - Salivary cortisol (ng/dL) | once every week, up to 3 month corrected age | No | |
Primary | Change of stress level of Parents - Salivary cortisol (ng/dL) | once every week, up to 3 month corrected age | No | |
Primary | Change of stress level of Patients - Salivary cortisol (ng/dL) | once every week, up to 3 month corrected age | No | |
Primary | Length of stay - days | up to 3 month corrected age | No | |
Primary | Incidence of necrotizing enterocolitis | up to 3 month corrected age | No | |
Primary | Incidence of retinopathia of prematurity | up to 3 month corrected age | No | |
Primary | Incidence of bronchopulmonary dysplasia | up to 3 month corrected age | No | |
Primary | Incidence of sepsis | up to 3 month corrected age | No | |
Primary | Duration of mechanical ventilation - days | up to 3 month corrected age | No | |
Primary | Time of feed initiation - days | up to 3 month corrected age | No | |
Primary | Time to full feed - days | up to 3 month corrected age | No | |
Primary | Number of days with parenteral nutrition | up to 3 month corrected age | No | |
Primary | Bayley scale - Psychomotor Developmental Index | up to 3 month corrected age | No | |
Primary | Bayley scale - Mental Developmental Index | up to 3 month corrected age | No | |
Primary | Number of changes in the primary health care professionals | up to 3 month corrected age | No | |
Primary | Noise level (decibel) | up to 3 month corrected age | No | |
Primary | use of resources (lab tests, X-rays, microbiological tests) | number of procedures | up to 3 month corrected age | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04046913 -
The ADDapt Diet in Reducing Crohn's Disease Inflammation
|
N/A | |
Active, not recruiting |
NCT04989907 -
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Active, not recruiting |
NCT04990258 -
A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
|
||
Completed |
NCT06216223 -
Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients
|
N/A | |
Enrolling by invitation |
NCT06015789 -
Self-care in Patients Affected by Inflammatory Bowel Disease and Caregivers' Contribution to Self-care
|
||
Recruiting |
NCT06065995 -
StoMakker Mobile Application
|
N/A | |
Recruiting |
NCT03282786 -
Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease
|
N/A | |
Recruiting |
NCT06002074 -
SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT04960826 -
Study of an Environmental Risk Factor in Crohn's Disease
|
||
Recruiting |
NCT05413941 -
Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease
|
N/A | |
Completed |
NCT03668249 -
A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
|
||
Completed |
NCT00721812 -
A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686
|
Phase 1 | |
Recruiting |
NCT05809999 -
IBD Neoplasia Surveillance RCT
|
N/A | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Recruiting |
NCT04991324 -
Cholecalciferol Comedication in IBD - the 5C-study
|
Phase 3 | |
Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
Not yet recruiting |
NCT05043818 -
A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
|
||
Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
Not yet recruiting |
NCT02858557 -
The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases
|
N/A |